Sonnet Biotherapeutics Holdings Inc. announced that it has received a notice from The Nasdaq Stock Market LLC indicating non-compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. The company reported stockholders' equity of $662,262, falling short of the required $2,500,000. Sonnet does not meet alternative compliance standards either, such as a market value of listed securities of at least $35 million or net income of $500,000. Nasdaq has given Sonnet until July 14, 2025, to submit a plan to regain compliance, with a possible extension of up to 180 days if the plan is accepted. The company's stock will continue trading under the symbol "SONN" as it explores options to meet the listing requirements. There are no assurances that the company's plan will be accepted or that it will successfully regain compliance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.